Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study

被引：35
|
作者：
Motzer, Robert [1 ]
Porta, Camillo [2 ,3 ]
Alekseev, Boris [4 ]
Rha, Sun Young [5 ]
Choueiri, Toni K. [6 ]
Mendez-Vidal, Maria Jose [7 ]
Hong, Sung-Hoo [8 ]
Kapoor, Anil [9 ]
Goh, Jeffrey C. [10 ,11 ]
Eto, Masatoshi [12 ]
Bennett, Lee [13 ]
Wang, Jinyi [13 ]
Pan, Jie Janice [14 ]
Saretsky, Todd L. [15 ]
Perini, Rodolfo F. [15 ]
He, Cixin Steven
Mody, Kalgi [14 ]
Cella, David [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[3] Univ Pavia, Dept Biomed Sci & Human Oncol, Pavia, Italy
[4] PA Herzen Moscow Oncol Res Inst, Dept Oncourol, Moscow, Russia
[5] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Reina Sofia, Cordoba Hosp, Maimonides Inst Biomed Res, Cordoba, Spain
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] McMaster Univ, Hamilton, ON, Canada
[10] South Brisbane, ICON Res, Brisbane, Qld, Australia
[11] Queensland Univ Technol, Brisbane, Qld, Australia
[12] Kyushu Univ, Fukuoka, Japan
[13] RTI Hlth Solut, Res Triangle Pk, NC USA
[14] Eisai, Nutley, NJ USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 06期
关键词：
EQ-5D;
D O I：
10.1016/S1470-2045(22)00212-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Copyright (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码：768 / 780
页数：13
相关论文
共 50 条
  • [21] Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro D.
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    Mccormack, Mary
    Massaad, Rachid
    Nguyen, Allison Martin
    Zhao, Qi
    Mckenzie, Jodi
    Prabhu, Vimalanand S.
    Makker, Vicky
    EUROPEAN JOURNAL OF CANCER, 2023, 186 : 172 - 184
  • [22] Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
    Motzer, Robert J.
    Choueiri, Toni K.
    Hutson, Thomas
    Rha, Sun Young
    Puente, Javier
    Lalani, Aly-Khan A.
    Winquist, Eric
    Eto, Masatoshi
    Basappa, Naveen S.
    Tannir, Nizar M.
    Vaishampayan, Ulka
    Bjarnason, Georg A.
    Oudard, Stephane
    Gruenwald, Viktor
    Burgents, Joseph
    Xie, Ran
    McKenzie, Jodi
    Powles, Thomas
    EUROPEAN UROLOGY, 2024, 86 (01) : 4 - 9
  • [23] Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
    Motzer, Robert
    George, Saby
    Merchan, Jaime R.
    Hutson, Thomas E.
    Song, Xun
    Perini, Rodolfo F.
    Xie, Ran
    Bapat, Urmi
    Puente, Javier
    ONCOLOGIST, 2023, 28 (06): : 501 - 509
  • [24] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [25] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [26] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma ( CLEAR): extended followup from the phase 3, randomised, open-label study (vol 24, pg 228, 2023)
    Choueiri, T. K.
    Eto, M.
    Motzer, R.
    LANCET ONCOLOGY, 2023, 24 (04): : E146 - E146
  • [27] Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae Lyun
    Perini, Rodolfo F.
    He, Cixin S. S.
    McKenzie, Jodi A.
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1241 - 1250
  • [28] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae-Lyun
    Perini, Rodolfo F.
    He, Cixin
    McKenzie, Jodi A.
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [30] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Ran
    Bapat, Urmi
    Ye, Weifei
    Jain, Rohit K.
    Fishman, Mayer N.
    EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
12345